Recombinant Human Protein EMSY (EMSY), partial

1. Altogether, 12 germline EMSY variants were observed in hereditary breast cancer and ovarian cancer families. Two alterations were located in the coding region, five alterations were intronic, and five alterations were located in the 3'untranslated region (UTR). Variant frequencies did not differ between cases and controls. These results suggest that the identified EMSY variants are likely neutral at the population level. PMID: 28738860
2. We conclude that EMSY and CCND1 work in collaboration and contribute to the pathogenesis of lung cancer. PMID: 28824300
3. Our results show a high frequency of EMSY amplification in MBC, thus pointing to a role of EMSY in the pathogenesis of this disease. EMSY amplification may be a new feature that might uncover underlying molecular pathways of MBCs and may allow for the identification of MBC subgroups with potential clinical implication for targeted therapeutic approaches. PMID: 27628328
4. EMSY overexpression impairs the repair of damaged DNA, suggesting that EMSY belongs to the family of BRCAness proteins PMID: 28099152
5. The rs2155219 single nucleotide polymorphism was significantly associated with atopic dermatitis. PMID: 26464032
6. identify a novel substoichiometric interactor of the complex, transcription factor ZNF131, which recruits EMSY to a large number of active, H3K4me3 marked promoters. PMID: 26841866
7. Eosinophilic esophagitis was associate with increased expression of C11orf30. PMID: 25407941
8. The association of higher levels of expression of C11orf30 may be involved in transcription repression of interferon-stimulated genes, and its association with sensitization to multiple allergens suggest that this locus is highly relevant for atopy. PMID: 25546184
9. Our study demonstrated that EMSY played an oncogenic role in the progression of ovarian cancer cells and EMSY might be a promising target for the treatment PMID: 25510665
10. Univariate analysis revealed a significant positive association between EMSY expression and lymph node metastasis, larger tumor size, as well as a non-significant relation with increased risk of recurrence. PMID: 24641409
11. EMSY is recruited to the miR-31 promoter by the DNA binding factor ETS-1, and it represses miR-31 transcription by delivering the H3K4me3 demethylase JARID1b/PLU-1/KDM5B PMID: 24582497
12. Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY PMID: 22315412
13. There are 2 independent signals, one in C11orf30 and the other in LRRC32, that are strongly associated with serum IgE levels. C11orf30-LRRC32 region may represent a common locus for atopic diseases via pathways involved in regulation of serum IgE levels PMID: 22070912
14. EMSY amplification does occur independently of CCND1 amplification in a minority of familial breast cancers, supporting its role as a possible breast cancer oncogene PMID: 21327470
15. EMSY amplification may mimic BRCA2 deficiency, at least by overriding RPA and PALB2, crippling the BRCA2/RAD51 complex at DNA-damage and replication/transcription sites PMID: 21409565
16. Sporadic ovarian cancer shows overexpression of EMSY at a prevalence similar to that found in breast cancer and the overexpression is correlated with the protein level. PMID: 20349280
17. co-amplification of CCND1 and EMSY identified a poor prognostic subset of ER-positive tamoxifen-treated patients PMID: 19636701
18. The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer. PMID: 14651845
19. The crystal structure of residues 1-108 of EMSY at 2.0 A resolution is reported; the structure contains both the ENT domain and the HP1beta/BS69-binding motif. PMID: 15947784
20. report the crystal structure of the ENT domain of EMSY; dimerisation of EMSY mediated by the ENT domain could provide flexibility for it to bind two or more different substrates simultaneously PMID: 15978617
21. common genetic variation in EMSY does not appear to have a role in development of breast or ovarian cancer PMID: 16029503
22. These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer. PMID: 16145051
23. Findings support the role of EMSY as a key oncogene within the 11q13 amplicon in ovarian cancer. PMID: 16236351
24. In an ovarian carcinoma cohort, RSF1 was amplified in 16% of the cases. It was correlated with serous histology and a worse prognosis. The 11q13 amplicon in ovarian cancer is likely driven by a cassette of genes rather than by a single oncogene. PMID: 18314909
25. gene copy numbers of EMSY in breast cancers PMID: 18393977
26. Data examine possible allelic imbalance in papillary thyroid cancer at EMSY, CAPN5, and PAK1, as candidate genes within 11q13.5-q14 region using a single nucleotide polymorphism-based analysis. PMID: 18787380
27. The identified components revealed factors involved in histone methylation and cell cycle control and include Ash2L, RbBP5, WDR5, HCF-1, DBC-1, and EMSY. PMID: 19131338

Show More

Hide All

HGNC: 18071

OMIM: 608574

KEGG: hsa:56946

STRING: 9606.ENSP00000334130

UniGene: Hs.352588